Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17764 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Mamitaro Ohtsuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Jichi Medical University, Shimotsuke, Japan. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide, Phosphodiesterase 4 Inhibitors, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen K.K..
Abstract (Originalsprache)
Apremilast is a phosphodiesterase 4 inhibitor approved for moderate to severe psoriasis in Japan. Apremilast significantly improved Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) both at 6 and 12 months in a previously published primary post‐surveillance study. Here, we performed a post hoc analysis of the surveillance data to evaluate patient characteristics, effectiveness, and safety among psoriasis patients who continued apremilast for 6 and 12 months. The PMS included 992 patients, of whom 646 of 992 patients continued treatment for 6 months and 509 of 992 patients subsequently continued treatment for 12 months. Baseline characteristics between these groups were similar. Among 992 patients, the treatment persistence rate was 65.1% at 6 months and 51.3% at 12 months after the start of apremilast treatment. PGA 0/1 response was 47.9% at 6 months and 60.8% at 12 months, whereas DLQI 0/1 responses at 6 months and 12 months were 38.5% and 58.7%, respectively. Among 646 patients who continued apremilast for 6 months, diarrhea was reported in 60 patients (9.3%), nausea in 35 patients (5.4%), and headache in 11 (1.7%) patients, which were mainly observed within the first month since treatment initiation. In 509 patients who continued apremilast for 12 months, diarrhea was reported in 43 patients (8.5%), nausea in 24 patients (4.7%), and headache in 6 (1.2%) patients; similar frequencies of these adverse reactions were observed within 6 months and between 6 and 12 months of follow‐up. It is important to continue apremilast by appropriately managing diarrhea and nausea in real‐world practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Igarashi Dermatology Higashi-Gotanda Clinic, Tokyo, Japan.
- Department of Dermatology, Fukuoka University, Fukuoka, Japan.
- Kojinkai Sapporo Skin Clinic, Sapporo, Japan.
ORCID-Profile: Mamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, Shinichi Imafuku, Masatoshi Abe, Akimichi Morita
Förderung
- Amgen K.K.
Zitieren
APA
Ohtsuki, M., Okubo, Y., Saeki, H., Igarashi, A., Imafuku, S., Abe, M., Saito, K., Ogawa, R., & Morita, A. (2025). Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17764
Vancouver
Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, et al. Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17764
BibTeX
@article{Ohtsuki2025,
author = {Ohtsuki, Mamitaro and Okubo, Yukari and Saeki, Hidehisa and Igarashi, Atsuyuki and Imafuku, Shinichi and Abe, Masatoshi and Saito, Katsuya and Ogawa, Ryuichi and Morita, Akimichi},
title = {Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17764}
}
EUVIMED